
Lexicon Pharmaceuticals, Inc.
NASDAQ:LXRX
0.36 (USD) • At close March 13, 2025
Overzicht | Financiële gegevens
Bedrijfsnaam | Lexicon Pharmaceuticals, Inc. |
Symbool | LXRX |
Munteenheid | USD |
Prijs | 0.357 |
Beurswaarde | 129,052,644 |
Dividendpercentage | 0% |
52-weken bereik | 0.28 - 2.62 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Lonnel Coats |
Website | https://www.lexpharma.com |
Over Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)